Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Gross Margin: 2024-2025

Historic Gross Margin for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to 100.00%.

  • Monte Rosa Therapeutics' Gross Margin changed negligibly% to 100.00% in Q3 2025 from the same period last year, while for Sep 2025 it was 100.00%, marking a year-over-year change of. This contributed to the annual value of 100.00% for FY2024, which is N/A change from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Gross Margin stood at 100.00%, which was down 0.00% from 100.00% recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Gross Margin peaked at 100.00% during Q1 2024, and registered a low of 100.00% during Q1 2024.
  • Moreover, its 2-year median value for Gross Margin was 100.00% (2025), whereas its average is 100.00%.